Remove Cannabis Remove Clinical Trials Remove Sleep
article thumbnail

First Ever Clinical Trial for Cannabis Migraine Treatment is Underway

Veriheal

Research and anecdotal reports have already displayed that cannabis can be used to treat the symptoms of migraines. However, there has not been a clinical trial assessing the efficacy of cannabis for migraines, at least not until now. The First Clinical Trial for Migraines and Cannabis.

article thumbnail

CBD Topical Medicine: What Does the Science Say?

Project CBD

Though the Canada-based authors conclude that transdermal delivery of CBD shows great promise and represents a potential novel treatment for chronic inflammatory pain, they also acknowledge that the jury is still out on its ability to achieve that key benchmark of offering tangible clinical benefits. The findings are mixed.

Topical 179
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

Could CBN really help you sleep? Consumer study data suggest yes.

The Cannigma

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. It also, allegedly, helps with sleep (more on that below). Here’s what they found.

Sleep 137
article thumbnail

Trouble Sleeping: Cannabis for Insomnia Relief

MMJ Recs

Many patients are turning to cannabis for insomnia relief, seeking its potential to improve sleep quality and duration. Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or experiencing non-restorative sleep despite having the opportunity to sleep.

Sleep 111
article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

Incannex (ASX: IHL) partners with Procaps to develop cannabis medicine for clinical trial on sleep apnea

Cannabis Law Report

to develop and manufacture soft gel capsules of Incannex’s cannabis medicine IHL-42X. The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. According to an article from the Lancet, sleep apnea affects 936 million adults globally.